scholarly journals Combination therapy of recalcitrant severe psoriasis with psoriatic arthritis, diabetes nephropathy, and liver cirrhosis

2021 ◽  
Author(s):  
Sebastian Zimmer ◽  
Mohamad Goldust ◽  
Shashank Bhargava ◽  
Joanna Wegner ◽  
Stephan Grabbe ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Psoriatic Arthritis ◽  
Combination Therapy ◽  
Severe Psoriasis ◽  
Diabetes Nephropathy

Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy

2002 ◽  
Vol 146 (1) ◽  
pp. 118-121 ◽  
Author(s):  
S. Iyer ◽  
P. Yamauchi ◽  
N.J. Lowe
Keyword(s):  
Psoriatic Arthritis ◽  
Combination Therapy ◽  
Severe Psoriasis

Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy

2002 ◽  
Vol 147 (4) ◽  
pp. 831-832 ◽  
Author(s):  
S.C. Davison ◽  
C.B. Bunker ◽  
T. Basarab
Keyword(s):  
Psoriatic Arthritis ◽  
Combination Therapy ◽  
Severe Psoriasis

scholarly journals Safety assessment of autologous stem cell combination therapy in patients with decompensated liver cirrhosis: a pilot study

2021 ◽  
Author(s):  
Mithun Sharma ◽  
Pavan Kumar Pondugala ◽  
Shashidhar Jaggaihgari ◽  
Sasikala Mitnala ◽  
Vemula Venkata Krishna ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Pilot Study ◽  
Combination Therapy ◽  
Safety Assessment ◽  
Decompensated Liver Cirrhosis

scholarly journals The Risk of Mortality among Psoriatic Patients with Varying Severity: A Nationwide Population-Based Cohort Study in Taiwan

2018 ◽  
Vol 15 (12) ◽  
pp. 2622 ◽  
Author(s):  
Ying-Xiu Dai ◽  
Ming-Chun Hsu ◽  
Hsiao-Yun Hu ◽  
Yun-Ting Chang ◽  
Tzeng-Ji Chen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Psoriatic Arthritis ◽  
Mortality Risk ◽  
Psoriasis Patient ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Severe Psoriasis ◽  
Control Group ◽  
Research Database ◽  
Control Subjects

Background: Previous studies showed conflicting results regarding the mortality risk in psoriasis patients with respect to disease severity and presence of psoriatic arthritis. This study aimed to determine the mortality risk in patients with mild and severe psoriasis and patients with psoriatic arthritis (PsA). Methods: A nationwide population-based cohort study was conducted based on data from the Taiwan National Health Insurance Research Database between 2002 and 2012. Incident psoriasis subjects were classified into two groups: psoriasis without arthritis and psoriasis with arthritis. Patients who had received systemic therapy and/or phototherapy were classified as having severe psoriasis; otherwise, patients were classified as having mild psoriasis. Control subjects without psoriasis were selected to match each psoriasis patient from the database within the same observational period. Cox proportional hazards analysis was used to compare the hazard ratio (HR) of time to death. Results: A total of 106,701 patients with psoriasis were included in this study. After controlling for demographics and comorbidities, psoriasis patients had a higher mortality risk compared with the control group (HR 1.41; 95% confidence interval (CI) 1.36 to 1.46). Compared with psoriasis alone, the mortality risk was not increased for PsA (HR = 1.01; 95% CI 0.93 to 1.10). Besides, severe psoriasis did not increase mortality risk compared with mild psoriasis (HR = 1.0; 95% CI 0.95 to 1.06). Conclusions: Patients with psoriasis had a higher mortality risk compared with control subjects, whereas psoriasis severity and presence of PsA had no impact on mortality risk in psoriasis patients.

scholarly journals Etanercept Therapy of Psoriatic Arthritis in a Patient with Liver Cirrhosis

2005 ◽  
Vol -1 (1) ◽  
pp. 1-1
Author(s):  
Michaela Lehnen ◽  
Tom Franckson ◽  
Andreas Korber ◽  
Stephan Grabbe ◽  
Joachim Dissemond
Keyword(s):  
Liver Cirrhosis ◽  
Psoriatic Arthritis ◽  
Etanercept Therapy

scholarly journals Impact of Adalimumab on Symptoms of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A Pooled Analysis of Randomized Clinical Trials

Dermatology ◽  
2010 ◽  
Vol 220 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Philip J. Mease ◽  
James Signorovitch ◽  
Andrew P. Yu ◽  
Eric Q. Wu ◽  
Shiraz R. Gupta ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Psoriatic Arthritis ◽  
Randomized Clinical Trials ◽  
Pooled Analysis ◽  
Severe Psoriasis

Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting

2018 ◽  
Vol 22 (6) ◽  
pp. 567-576 ◽  
Author(s):  
Wayne P. Gulliver ◽  
Shane Randell ◽  
Susanne Gulliver ◽  
Valerie Gregory ◽  
Sean Nagle ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Clinical Research ◽  
Plaque Psoriasis ◽  
Biologic Therapy ◽  
Severe Psoriasis ◽  
Second Line ◽  
Biologic Therapies ◽  
Biologic Treatment ◽  
Treatment Pathways ◽  
Severe Plaque Psoriasis

Plaque psoriasis affects approximately 2% to 3% of the global population, with psoriatic arthritis observed in approximately 20% to 30% of these individuals. Upon advances in research pathophysiology and treatment over the past decade, biologic therapies have been used more to treat moderate to severe psoriasis. In Canada, reimbursement bodies have defined prior authorization criteria to determine patient eligibility for funding of biologic treatments in moderate to severe plaque psoriasis. Generally, patients will have been treated with conventional therapies such as topical steroids, phototherapy, or systemic treatments such as methotrexate and cyclosporine before starting a biologic therapy. In difficult cases or severe flares in otherwise controlled disease, practitioners may augment the regimen with one or more conventional treatments. The objective of this observational report was to identify treatment pathways for psoriasis and psoriatic arthritis patients in Canada by examining initial biologic treatment and subsequent treatment optimization patterns for informed reimbursement discussions and decisions. A retrospective chart review was conducted at Newlab Clinical Research using medical records of patients who received at least 1 of 4 biologic agents approved at that time of the survey in Canada for the treatment of plaque psoriasis (adalimumab, etanercept, infliximab, ustekinumab). The study population consisted of patients who had moderate to severe plaque psoriasis, diagnosed by a dermatologist, for at least 6 months before the study index date and who attended Newlab Clinical Research between 2008 and 2013. All current and previous agents prescribed for the treatment of psoriasis were captured. A total of 248 patients with psoriasis treated with biologics were identified, of whom 27 (10.9%) were also diagnosed with psoriatic arthritis. Prior to initiating treatment with a biologic, most patients (72.1%) were treated with (or contraindicated to) methotrexate/cyclosporine. Treatment was supplemented with topical agents (70.6%) and/or followed by a course of ultraviolet light phototherapy (51.6%). Only 2.4% of patients were treated with a biologic first. Of 248 patients treated with biologics, almost half (47.6%) needed add-on therapy, whereas 16.5% of patients had an increase in dose or dosing interval. Furthermore, 14.1% of patients added a topical agent, 10.5% a topical steroid, or 6.5% a course of phototherapy while continuing biologic therapies. Finally, 30.4% of patients switched to another biologic treatment. Adalimumab was the most common agent used as a second-line agent (37.2%), and patients who started on adalimumab mainly switched to ustekinumab as a second-line agent (73.9%). Infliximab was the agent least often used as second-line therapy.

Sign in / Sign up

Export Citation Format

Share Document